indivior plc said wednesday that it expects higher annual peak revenue for its opioiduse treatment sublocade forecasted mediumterm margin expansion and strong net revenue growth and backed its outlook for fiscal 2022 the ukbased pharmaceutical company increased its peak annual revenue expectation for sublocade to more than 15 billion in the longer term and said it continues to expect the drug to achieve a net revenue run rate of 1 billion by the end of 2025 in the mediumterm indivior said it expects to achieve a doubledigit percentage net revenue compound annual growth rate this will primarily be driven by sublocade in the us and a growing net revenue contribution from perseris a schizophrenia treatment indivior expects to achieve significant operating margin expansion over the mediumterm driven by an improving gross margin and focused management of operating expenses the company said indivior reiterated its fiscal 2022 guidance as it was published in october it said the company will hold a capital markets day on wednesday in new york